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Purpose. The aim of this study was to identify patient and physician factors related to enrollment onto
Gynecologic Oncology Group (GOG) trials.
Methods. Prospective study of women with primary or recurrent cancer of the uterus or cervix treated at a
GOG institution from July 2010 to January 2012. Logistic regression examinedprobability of availability, eligibility
and enrollment in a GOG trial. Odds ratios (OR) and 95% conﬁdence intervals (CI) for signiﬁcant (p b 0.05) results
reported.
Results. Sixty institutions, 781 patients, and 150 physicians participated, 300/780 (38%) had a trial available,
290/300 had knownparticipation status. Of these, 150women enrolled (59.5%), 102 eligible did not enroll (35%),
38 (13%) were ineligible. Ethnicity and specialty of physician, practice type, data management availability, and
patient age were signiﬁcantly associated with trial availability. Patients with N4 comorbidities (OR 4.5; CI 1.7–
11.8) had higher odds of trial ineligibility. Non-White patients (OR 7.9; CI 1.3–46.2) and patients of Black
physicians had greater odds of enrolling (OR 56.5; CI 1.1–999.9) in a therapeutic trial. Signiﬁcant patient
therapeutic trial enrollment factors: belief trial may help (OR 76.9; CI 4.9–N1000), concern about care if not on
trial (OR12.1; CI 2.1–71.4), pressure to enroll (OR .27; CI 0.12–.64), caregiving without pay (OR 0.13; CI .02–.84).
Signiﬁcant physician beliefs were: patients would not do well on standard therapy (OR 3.6; CI 1.6–8.4), and trial
would not be time consuming (OR 3.3; CI 1.3–8.1).th Annual Meeting of The Society of Gynecologic Oncology held in Tampa, Florida on March 22–25, 2014.
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102 S.E. Brooks et al. / Gynecologic Oncology 138 (2015) 101–108Conclusions. Trial availability, patient and physician beliefs were factors identiﬁed that if modiﬁed could
improve enrollment in cancer cooperative group clinical trials.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
It is reported that 80% of clinical trials struggle to meet their set ac-
crual targets [1]. Cheng et al. reported that of more than 500 NCI Cancer
Therapy Evaluation Program (CTEP) trials, 40% failed to achieve mini-
mum patient enrollment, and more than three of ﬁve phase III trials
failed to do so [1]. Enrollment in cancer trials has, for decades been
low for all groups, with racial and ethnic minorities, women, and the
elderly reported to be less likely to enroll in cooperative group cancer
trials than whites, men, and younger patients, respectively. Arising
from concern of the ability of cooperative groups to conduct timely,
large-scale, innovative clinical trials needed to improve patient care, a
recent Institute ofMedicine report recommended changes to the clinical
cooperative group system to enhance efﬁciency and participation of
patients and physicians in clinical trial research [2,3].
For patients who have access to clinical trials, through their
treating physician, it is recognized that patient accrual is inﬂuenced
by a number of factors. In 2007, Howerton and colleagues reviewed
18 studies examining recruitment of under-represented populations
to cancer clinical trials and determined that patient accrual was sig-
niﬁcantly inﬂuenced by provider attitudes [4]. Other factors inﬂuenc-
ing enrollment include: awareness and individual level inﬂuences,
interpersonal level factors, institutional and clinical practice level in-
ﬂuences, and community and public policy level inﬂuences [5–10].
Few studies have included both the patient and provider perspective
when examining factors inﬂuencing trial enrollment in the setting of
real-time decision-making.
In 2010, the Gynecologic Oncology Group (GOG), amulti-disciplinary
cooperative group dedicated to clinical research in gynecologic
cancers consisted of nearly 200 institutions across the country.
Over the course of a decade, the GOG recruited more than 41,000
women onto clinical trials [11]. No prior published studies have
examined trial availability, eligibility and enrollment in women with
gynecologic cancer.
Given that multiple factors inﬂuence participation in clinical trials
and the paucity of literature in gynecologic cancers,we sought to identify
modiﬁable factors associatedwith clinical trial availability, eligibility, and
enrollment for patients with cancer of the cervix and endometrium in
order to inform future interventions.
Methods
GOG Protocol 247 was a prospective multi-institutional observa-
tional study of womenwith newly diagnosed primary or recurrent can-
cer of the uterine corpus or cervix under the care of a GOG participating
gynecologic oncologist, medical oncologist, or radiation oncologist at a
GOG member or afﬁliate institution during the period 7/19/10–1/17/
12. The project received local Institutional ReviewBoard review for par-
ticipating sites. Each primary GOG physician completed a registration
form indicating; year of birth, race, ethnicity, specialty, years of experi-
ence, institutional afﬁliation, practice type and the type of staff dedicat-
ed to research. Each patient completed the patient registration form
indicating; race, ethnicity, income, and then completed the patient
quality of life questionnaire (Fig. 1). All participants signed an institu-
tionally approved informed consent to participate in the current
study, including Health Insurance Portability and Accountability Act
(HIPAA) authorization. Consistent with institutional and physician
practices, patients with a trial available and who were eligible were
invited to enroll in a therapeutic trial.Once a decisionwasmade to enroll or not enroll the patient in a GOG
clinical trial, the GOG physician completed the Physician Follow-up
Questionnaire.
Logistic regression was applied to examine the effect of patient and
physician factors on the probabilities of availability, eligibility, and en-
rollment on a GOG trial. Adjusted Odds ratios (OR) and 95% conﬁdence
intervals (CI)were reported for statistically signiﬁcant results (p b 0.05)
for the ﬁnal selected logistic regression model.
Questionnaire variables ranging from strongly disagree to strongly
agree were recoded into two categories (usually agree or disagree) to
provide cell counts large enough for univariate Chi Square tests to be
valid. Similarly, other categorical variable codes were collapsed as
needed to allow a valid univariate Chi-square test for associations
with each outcome. Variableswith invalid Chi Square testswere deleted
from further consideration. Univariate tests of association of outcomes
with continuous predictors were performed using t-tests or Mann–
Whitney U-tests as appropriate.
Each variable found to be signiﬁcantly associated with univariate
tests was included in initial logistic regressionmodels and backward se-
lection was used to reduce the model to include signiﬁcant (p b 0.05)
variables and any other variables that, if deleted would result in the
deletion of a previously signiﬁcant variable. At each step, the factor
with the largest p-value was deleted, unless its deletion resulted in
another variable that had been signiﬁcant becoming non-signiﬁcant.
In this case, the deleted variable was added back into the model and
the variable with the next largest p-value was deleted. The ﬁnal models
contained only signiﬁcant factors or non-signiﬁcant factors that, when
deleted, resulted in a loss of signiﬁcance.
The results include the ﬁnal models resulting from the backward se-
lection strategy, along with follow-up pairwise comparison to describe
signiﬁcant effects. Adjusted OR's and 95% conﬁdence intervals were
used to make the pairwise comparisons.
Results
During the study period, 781 women from 60 sites and their physi-
cians completed the GOG 247 registration and questionnaire. Patients
and their physicians participated from 28 states across the continental
US. Twenty-four of the participating sites were primary GOG sites and
the remaining sites were afﬁliates and nearly 1/3 of the patients were
enrolled from CCOP sites.
Patient and physician ethnicity, race and age distributions of the pa-
tients and physicians participating in GOG 247 are presented in Table 1.
Gynecologic oncologists enrolled 91% of the patients, and radiation and
medical oncologists enrolled the remaining 9% of women. Forty seven
percent of physicians practiced in an academic center, 21% a hospital-
based practice, 28% private practice, and 4% were in other practice
settings.
A GOG treatment trial was available at the institution for 300
(38%) of the participating women. Ten of these were deemed eligible
by their physician but it was not reported whether they participated
in a GOG treatment trial or not. Of the 290 patients with a trial avail-
able and known participation status, 102 (35%) were eligible but did
not enroll, 38 (13%) were not eligible and 150 (52%) enrolled in a
treatment trial. Those enrolled represented 150/252 (59.5%) of pa-
tients who enrolled or were eligible for a trial and did not enroll.
The distributions of these 290 patients with a trial available into
these eligibility/enrollment categories are presented by race and
overall in Table 2.
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cancer trials and 4 uterine sarcoma trials were open in the GOG. The
mean number of studies open at each site was 4.3 with a median of 3
and a range of 0–26.Physician and practice characteristics and trial availability
Patients of physicians with Hispanic/Latino ethnicity had lower odds
of having a trial available than those of non-Hispanic/Latino physicians
(OR 0.25; CI 0.8, 0.75, p = 0.0135). There were no differences in trial
availability for patients among physicians of different racial groups. A de-
scription race and ethnicity of physicians, and the availability, eligibility
and enrollment of patients onto a clinical trial are found in Supplemental
Table 1 (on line).
Physician subspecialtywas related to trial availability. Gynecologic on-
cologists (OR; CI 2.1, 20.3; p = 0.0014) and medical oncologists (OR 5.0;
CI 1.4, 18.6; p= 0.0156) had higher odds of having trials available for pa-
tients with cervical or uterine cancer compared to radiation oncologists.
Physicians in academic practice (OR 8.56; CI 2.57, 28.6, p= 0.0005),
hospital based practice (OR 9.63; CI 3.89–23.78, p b 0.0001) and other
practice settings (OR 16.48; CI 5.27, 51.5, p b 0.0001) were more likely
to have trials available than those in private practice.
Dedicated personnel resources were important in determining trial
availability. Institutions with no data management staff dedicated to
GOG were less likely to have a trial available for their patients (OR 0.25;
CI 0.1, 0.55, p = 0.0006) than institutions with GOG data management
staff. In summary, ethnicity, specialty and practice type of physician, andGOG PROTOCOL # 247 
1. Clinical trials are important for the future care of p
2. Overall, I have a good impression of my doctor. 
3. I felt pressure to enter a clinical trial. 
4. I expect to do well with treatment whether or not I
5. Enrolling on a clinical trial might help me. 
6. I had enough information to make a decision abou
7. I had enough time for my decision. 
8. Family and friends help me make decisions about 
9. Participating in a clinical trial will take up a lot of 
10. Participating in a clinical trial will cost me extra m
11. I am concerned about side effects I might have wit
12. My doctor helped me to decide whether or not to e
13. My doctor wanted me to go on a trial.              
14. I have concerns about what kind of care I would re
15. The nurse(s) provided me with information that he
16. The doctor provided me with information that help
17. I know of someone treated on a clinical trial that h
18. I know of someone treated on a clinical trial that h
19. I would consider entering a clinical trial in the futu
20. Getting transportation for doctor and hospital visit
21. Do you provide care, without being paid, to a child
member or friend? If yes, how many hours a week
22. How many people, including yourself, did your to
year? 
23. Did you have a primary care physician at the time 
 If yes, when did you last see your primary care ph
24. Have you ever participated in a clinical trial?
25. Do you know someone who has participated in a cl
26. Please rate your overall QUALITY OF LIFE over t
And 10 represents "as good as it can be."  
 As bad as it can be   
Fig. 1. Questioavailability and adequacy of datamanagement infrastructurewere signif-
icantly associated with trial availability.
Patient characteristics and trial availability
Overall, trialswere available for 33% of Black patients, 37.8%ofWhite
patients and 48% of Asian patients, (p = 0.1680). Trials were available
for just 7% of Hispanic/Latina women compared with 43% of non-His-
panic/Latina women (p = 0.0001). We determined that there were
also differences in the percentage of patients with available trials by
age. Patients over the age of 71 were less likely to have trials available
when compared with patients under the age of 41 (OR 0.4; 0.2, 0.8,
p = 0.0097), 41–50 (OR 0.51; 0.28, .93, p = 0.0267), and 51–60 (OR
0.55; 0.34, 0.88. p = 0.0120). A description race and ethnicity of
patients, trial availability, eligibility and enrollment of patients is
found in Supplemental Table 2 (on line).
Trialswere available for 50% ormore ofwomenwith Stage IVdisease
(line Table 3).
Treatment recommended by physicians who participated in this study
Of the 780 patients enrolled in this study who could be included in
any of our analyses (complete data was not available for one patient),
in 29% (n = 224) the physician offered no further treatment, in 18%
(n = 143) the physician planned treatment on a GOG trial (4 of these
143, however, did not enroll in a GOG treatment trial), in 1.4% (n =
11) participation in a pharmaceutical study was planned (1 of these
11, however, enrolled in a GOG treatment trial), in 6.3% (n = 49) anatients. 
 go on a trial.                    
t participating in the clinical trial. 
treatment. 
my time. 
oney. 
h experimental treatment.                           
nter a trial.                                        
ceive if I do not go on the trial. 
lped me understand the clinical trial.               
ed me understand the clinical trial.        
ad a good experience 
ad a bad experience. 
re if it was offered. 
s required for a clinical trial would be difficult for me.
, elder, or disabled person?  This may be a family 
 do you spend providing care on average? 
tal household income support during the last calendar
of your diagnosis (primary or recurrent?)?  
ysician? 
inical trial?                                     
he past week. A 0 represents "as bad as it can be" 
   As good as it can be           
nnaire.
27. What is your current employment status? 
(Please mark all that apply) 
O Employed full-time 
O Employed part-time 
O Not employed for pay, not seeking paid employment
O Not employed for pay, but seeking paid employment
O Retired 
O Homemaker 
O Student 
O Volunteer 
28. Which category best represents your total household income 
Last calendar year, from all sources before taxes? 
O $10.000 - $19,999 
O $20.000 - $29.999 
O $30,000 - $39,999 
O $40,000 - $49,999 
O $50,000 - $69,999 
O $70,000 - $99,999 
O $100,000 or more 
29. In what region were you born? 
O North America (including US and Canada) 
O South America   
O Africa 
O Asia   
O Europe 
O Australia 
30. What type of transportation do you use to get to the 
Hospital or clinic? 
O Private Car 
O Taxi 
O Public Transportation 
O Friend/Relative 
O Walking 
O Other 
31. How long does it take you to travel to the hospital or clinic?
O Less than 30 minutes 
O 30 minutes to 1 hour 
O More than 1 hour but less than 2 hours 
O 2 hours or longer 
32. How far do you live from the hospital or 
clinic? 
O Less than 10 miles 
O 10 to 20 miles 
O 21 to 40 miles 
O more than 40 miles 
33. In general do you speak 
O Only English 
O English better than my other language 
O Both languages equally 
O My other language better than English 
O Only my other language 
34. What is your current marital status? 
O Married or living with a partner 
O Separated or divorced 
O Widowed 
O Never married 
35. What is the highest level of  
education you have completed? 
O No formal schooling 
O Grade school 
O Some high school 
O High school graduate or GED 
O Some college or technical school 
O College graduate or beyond 
Answer question 36 ONLY if you are NOT 
going to participate in a treatment clinical 
trial. 
36. I am not going to participate in a  
treatment clinical trial at this time 
because: 
O It was not offered 
O I am concerned about safety 
O I am concerned about time 
O I am concerned about cost 
O I don’t understand the trial 
O Other 
_____________________________ 
Fig. 1 (continued).
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GOG treatment trial), and in 45.3% (n = 353) treatment off protocol
was planned (9 of these 353 women, however, enrolled in a GOG trial).
Physician race and ethnicity and trial eligibility
Thepercentage of eligible patients did not vary signiﬁcantly by race of
thephysician however, patients ofHispanic/Latino physicians hadhigher
odds of being ineligible for a trial (OR 28.87; 2.33–358.86, p = 0.009)
(Table 4).
Patient eligibility for GOG clinical trial (n = 300 patients with a trial
available)
For the 300 patients forwhom a trial was available therewere no sig-
niﬁcant differences in percent eligible by race of the patient. Supplemen-
tal Table 3 (on line) displays eligibility and Supplemental Table 4 (on
line) displays enrollment of women by stage of disease and tumor type.Multiple comorbid illnesseswere negatively associatedwith eligibil-
ity for a clinical trial. Eighty six percent of women (240/276) with 4 or
fewer comorbidities were eligible for a trial when one was available
and 15/24 or 62% of women with more than 4 comorbidities were
eligible for a trial when one was available (p = 0.0019), Table 4.Physician characteristics and trial enrollment of eligible or presumed
eligible patients with known enrollment outcome (n = 290)
Physician attitudes associated with higher odds of enrollment in-
cluded believing that their patient would not respond well to standard
treatment (OR 3.07; CI 1.56–8.26, p= 0.0027). In addition, if the physi-
cian believed that the trial would not be time consuming for the patient,
(OR 3.27; CI 1.31–8.13), the odds of patient enrollment were higher
than if they believed the trial would take up a lot of the patient's time.
Black physicians had higher odds of enrolling patients on a trial
(OR 56.5; 1.06–N999.999) compared to White or Asian physicians
(Table 5).
Table 1
Race and ethnicity of patients and physicians enrolled in this study (Gynecologic Oncology
Group Study Number GOG 247).
Patient and physician demographics Patient n = 781 (%) Physician n = 150 (%)
Age
20–29 8 (1) 0
30–39 51 (6.5) 25 (16.7)
40–49 88 (11.3) 53 (35.3)
50–59 205 (26.2) 45 (30)
60–69 259 (33.2) 22 (14.7)
70–79 129 (16.5) 4 (2.7)
80–89 37 (4.7) 1 (.7)
N=90 4 (.5) 0
Ethnicity
Hispanic 24 (3.1) 7 (4.7)
Non-Hispanic 755 (96.7) 136 (90.6)
Unknown 2 (0.2) 7 (4.7)
Race
Asian 23 (2.9) 18 (12)
Black 63 (8.0) 6 (4)
American Indian 20 (2.6) 0
White 665 (85.1) 123 (82)
Native Hawaiian/Paciﬁc Islander 2 (0.2) 0
Unknown 8 (1.0) 3 (2)
Table 3
Trial availability percentage by stage of disease and by tumor type.
Cervix trial available A/B (%) Uterine trial available C/D (%)
Stage of disease/status
Stage I 8/63 (12.7) 100/356 (28)
Stage II 5/32 (15.6) 31/64 (48)
Stage III 5/27 (18.5) 76/112 (68)
Stage IV 8/16 (50) 20/33 (60)
Persistent
4/4 (100) 1/4 (25)
Recurrent 13/18 (72) 29/51 (57)
A = number of cervical patients with trial available.
B = number of cervical patients.
C = number of uterine patients with trial available.
D = number of uterine patients.
(n = 780, data unavailable for 1 patient).
105S.E. Brooks et al. / Gynecologic Oncology 138 (2015) 101–108To examinewhether the differences in enrollment seen among phy-
sicians of different racial groups were uniform across patients of all
races, or if they were patient-race speciﬁc, a logistic regression model
that included the race of the physician by race of patient interaction
was performed. This analysis revealed that Black physicians had high
rates of enrollment of patients uniform across all races but the low
enrollment rate of patients with Asian physicians was speciﬁc to
White patients.
Patient characteristics associated with clinical trial enrollment
Patient factors associated with higher odds of enrollment were:
Non-white patient race (OR 7.89, 1.35–46.19), the patient believing
the clinical trial might help them (OR 76.9; 4.8–N 1000), believing
their doctor wanted them to go on a trial (OR 13.8; 2.72–71.42), or con-
cern about the care theymight receive if theywere not on a clinical trial
(OR12.12; 2.06–71.36). Patients who felt pressured to enter a trial (OR
0.27; 0.12–0.64) or thought participating in a trial would take up a lot
of time (OR 0.18. 0.034–0.89) had lower odds of enrolling. Performing
duties as a caregiver to a friend or family member without pay was
also associated with lower odds of enrollment (0.125; 0.019–0.84)
(Table 5). Supplemental on line Tables 5 through 7 display additional
patient variables associated with availability, eligibility and enrollment.
Discussion
This study represents a unique prospective examination of patient
and physician factors associated with entry onto a Gynecologic
Oncology Group trial. This is one of the ﬁrst such studies conductedTable 2
Eligibility/enrollment outcome distribution of patients with a trial available (n = 290), by race
Patient race Eligible, not enrolled
(%) among patients with
a trial available
Enrolled
(%) among patie
a trial available
White 94 (40) 107 (45)
Black 2 (7) 24 (83)
Asian/Asian/White 2 (14.2) 11 (78.6)
Native American 1 (12.5) 6 (75)
Hawaiian/PI 1 (100) 0
Unknown 2 (50) 2 (50)
Overall total (%) 102 (35) 150 (52)documenting patient and physician perspectives in real time as the de-
cisions about enrolling in a therapeutic trial were beingmade. Strengths
of this study include: the prospective andmulti-institutional nature, the
inclusion of the perspectives of physicians and patients, and the analysis
of trial availability, patient eligibility, and enrollment outcomes.
Limitations of this study include the fact that approximately 1/3 of
GOG centers opened this trial and it is not possible to know who was
screened and who did not enroll. The ﬁndings are provocative and
bring new information about what factors inﬂuence clinical trial enroll-
ment in women with cervical and uterine cancer in the cooperative
group setting.
Overall, clinical trials were available for just 38% of patients. Trials
were more likely to be available in hospital based or academic settings
with dedicated infrastructure and data management support. A high
level of sustained dedicated support for the conduct of clinical trials in
community settings is vital for community oncologists to be able to
participate in clinical trial networks and for results of clinical trials to
be adopted in community settings. This point was emphasized in a
2010 Institute of Medicine report, that noted that uptake of evidence-
based practices are slow when practitioners are not engaged in the
research that supports the changes [12].
Overall, 13% of women in this study for whom a trial was available
and whose enrollment outcome was known, were not eligible for a
GOG clinical trial. Given that the number of individuals screened for
trials is not routinely captured and reported, it is uncertain if this
percentage is modiﬁable, however, clinical trial eligibility represents
one of the few accrual factors directly controlled by the lead study
investigator. Although calls have been made to simplify and provide
rationale for study inclusion and exclusion criteria, it is not clear
that a common exclusion such as a prior cancer diagnosis interferes
with study outcomes in all cases [13]. Exclusions for comorbidity po-
tentially represent a modiﬁable factor in order for study populations
to more accurately reﬂect the population affected by the condition
of interest [14–17].
Traditionally, time constraints and logistical barriers such as trans-
portation and the necessity of caring for others without pay have not
been factored into research infrastructure considerations or feasibilityand overall.
nts with
Not eligible
(%) among patients with
a trial available
Race of women with a
trial available
(%)
33 (14) 234 (81)
3 (10) 29 (10)
1 (7) 14 (4.8)
1 (12.5) 8 (2.7)
0 1 (0.03)
0 4 (1.3)
38 (13) 290 (100)
Table 4
Logistic regression analysis: variables associated with trial eligibility/ineligibility among patients with a trial available (n = 290).
P-value Odds ratio Lower bound of the 95% CI Upper bound of the 95% CI
Ethnicity of physician non-Hispanic 0.009 28.87 2.32 358.86
I have concerns about what type of care I would receive if I don't go on the trial 0.0322 5.56 1.16 29.4
Comorbidity b4 vs. N4 0.0019 4.50 1.74 11.76
106 S.E. Brooks et al. / Gynecologic Oncology 138 (2015) 101–108of enrollment. However, given that these factors were associated with
enrollment in this study, they warrant pro-active consideration and
are potentially modiﬁable with navigator and social service support
[18,19].
The race of the patient and the race of the doctor were associated
with the likelihood of clinical trial enrollment. Overall, Black physicians
had high rates of enrollment of patients uniform across all races. The
enrollment rate of patients with Asian physicians was speciﬁc to
White patients. Stated differently, this interaction is the result of a
difference in the enrollment of White patients when the race of the
physician was White, Asian or Black. In the group of women that were
eligible for a trial, 45% ofWhitewomen enrolled in a trial in comparison
with 83% of Black women, 78% of Asian women, and 75% of Native
American Women. We determined that White women enrolled at a
lower rate relative to the fraction they represented in the study and
Non-White women enrolled at a rate higher than the fraction of the
population they represented in the study. Restated, White women rep-
resented 81% of the 290 women in this study who had a trial available
for whom enrollment status was known and 71% of the 150 women
who subsequently enrolled in a GOG uterine or cervical cancer trial.
Black women represented 10% of 290 and 16% of the 150 who subse-
quently enrolled in a GOG uterine or cervical trial, Asian women
comprised 4.8% of the 290 and 7.3% of those who enrolled. This study
had a 5 to 8-fold higher percentage of Native American women in com-
parison with previously conducted GOG studies. They represented 2.7%
(8/290) of this study population and 4% (6/150) of the women in this
study that enrolled in a GOG trial. These ﬁndings bring a different di-
mension to the inﬂuence of race and cultural perspective in medical
and clinical trial settings [20,21,22].
The relatively high percentage of enrollment among Blackwomen in
our study is consistent with a report by Wendler et al., however given
ourﬁndings documenting the patient perspective on factors inﬂuencing
enrollment, this should not be interpreted as evidence that barriers to
non-white enrollment no longer exist and can be ignored [23]. It is likely
that there are culturally inﬂuenced issues of perceived beneﬁt or risk of
harm playing a role in a patient's decision to enter both this study and,
more generally, clinical trials [24,25]. The very high enrollment rates
(~80%) among minority women may reﬂect women who were
concerned about their treatment if they did not go on a study. There
continues to be a great opportunity to address enrollment onto research
trials through investigator training that includes acknowledgment of
the role of cultural perspectives [26]. Patients of Hispanic/LatinoTable 5
Logistic regression analysis: variables associated with trial enrollment.
Race doctor Asian vs. White
Race doctor Black vs. White
Patient race non-White vs. White
I felt pressure to enter a trial (agree vs. disagree)
Enrolling in a clinical trial might help me (agree vs. disagree)
Participating in a trial will take up a lot of time (agree vs. disagree)
My doctor wanted me to go on trial (agree vs. disagree)
I have concerns about the type of care I would receive if I do not go on trial (agree vs. disa
I would consider entering a clinical trial in the future if it was offered (agree vs. disagree)
Getting transportation for doctor and hospital visits required for a clinical trial would be difﬁcu
Do you provide care without being paid to a child, elder or disabled person? This may be a famphysicians in this study were less likely to be eligible for GOG studies.
Hispanic/Latina women participated at a rate of 3% and no Hispanic/
Latina women in this study enrolled in a GOG trial. While the precise
reasons for these ﬁndings are unknown, these ﬁndings are of concern
and represent a signiﬁcant opportunity to address the needs of this
growing demographic group [27–29].
The patient's perception of being helped by the trial and, the
perception of the care they might receive if they were not on trial was
positively associated with clinical trial enrollment. Conversely, odds of
enrollment were lower if the patient felt pressure to enter a trial.
From the physician's perspective, if the doctor felt that the trial would
beneﬁt the patient compared with standard of care the odds of
enrollment were higher.
Approaching patients regarding clinical trials requires a delicate
balance. It is possible that true pressure existed, or that enthusiasm
was interpreted as pressure. This is a reminder of the importance of
frankly acknowledging that it is simply not known which treatment is
better when comparing an experimental treatment to a standard treat-
ment. Given historical missteps in informed consent, which remain a
barrier to participation in research, our ﬁndings reveal an opportunity
to enhance training of the research team with speciﬁc focus on ethical
considerations in research and in building trust [30–34]. Cultural appro-
priateness and sensitivity, and involvement of minority physicians are
noted to be important strategies for increasing enrollment of minority
patients in research. Possible approaches include implementation of
cultural competency training programs accompanied by evaluation
and metrics along with tailored, recruitment processes focused on re-
cruitment ofminority physicians into research [6,35]. This is particularly
relevant given that it is stated that by 2045, people of non-white
race and Hispanic/Latino ethnicity are projected to account for the
majority of the U.S. population [36]. Currently, just 13.5% of practicing
physicians identiﬁed as Black, American Indian or Alaska Native,
or Hispanic/Latino [37]. In our study, 4% of physicians were Black,
4% were Hispanic. None of the physicians were American Indian or
Alaska Native, Hawaiian or Paciﬁc Islander. Active intervention will be
required to address this important modiﬁable factor highlighted by
our ﬁndings.
In summary, we determined that there aremodiﬁable infrastructure
factors associatedwith availability of clinical trials and potentiallymod-
iﬁable patient and physician factors associated with patient eligibility
for clinical trials. We also determined that variations of enrollment
based on the race or ethnicity of the doctor or patient, are potentiallyP-value Odds ratio Lower bound
of the 95% CI
Upper bound
of the 95% CI
0.0004 0.03 0.005 0.22
0.0465 56.50 1.06 N999.999
0.0219 7.893 1.35 46.19
0.0016 0.27 0.12 0.64
0.0020 76.9 4.80 N1000
0.0355 0.18 0.034 0.89
0.0016 13.80 2.717 71.42
gree) 0.0058 12.12 2.057 71.36
0.0022 40.00 3.780 500
lt for me (agree vs. disagree) 0.0059 0.109 0.022 0.527
ily member or friend (yes vs. no) 0.0323 0.125 0.019 0.84
107S.E. Brooks et al. / Gynecologic Oncology 138 (2015) 101–108modiﬁable factors that relate to the doctor/patient interaction. Health
systems and practices should appreciate that in addition to investiga-
tors, patients and a minimum level of dedicated infrastructure,
a formalized process to address cultural competence training will
promote effective enrollment of patients in clinical trials. Such training
can include education aimed at increasing sensitivity and awareness;
the provision of relevant multicultural knowledge, health and
demographic information; and skills building in bicultural and bilingual
interviewing and patient assessment. Assessment of patient satisfaction
and correlation of recruitment with the burden of disease in the catch-
ment area of interest would add additional dimensions of understand-
ing to local challenges inﬂuencing recruitment to clinical trials [38].
The newly consolidated cooperative group structure (NRG Oncolo-
gy) and its committees that speciﬁcally focus on clinical trial accrual
have the potential to draw on best practices from each of the legacy
groups and create new processes and programs that will enhance train-
ing of investigators, foster development of a diversiﬁed workforce
and develop recruitment strategies designed to meet the needs of
increasingly diverse populations. These steps would facilitate the goal
of comprehensive inclusion of participants in clinical trials to assure
expeditious completion and generalizability of clinical trial results
[38–40].
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